T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in ...

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with ...

Pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

Panelists discuss how medication adherence significantly impacts chronic myeloid leukemia (CML) treatment outcomes, with research showing even small differences between 90% and 95% adherence to ...

Panelists discuss how patient education plays a crucial role in ensuring adherence to tyrosine kinase inhibitor (TKI) therapy by building trust through clear explanations of medications and expected ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma.

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...